Seragon Completes Pre-Clinical Study of Aging Intervention Candidate SRN-901

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Seragon-SRN-901

More Like This

Extracellular Nanoparticles Sourced From Another Species Reverses Biological Age of Rats by More Than 50%

Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders

Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders

Rejuveron Life Sciences AG Rebrands as Centenara Labs AG and Provides Latest Clinical Updates

PR Newswire associated0

LifeSpan Vision Ventures Makes 7th Investment in Pursuit of Longevity Mission

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR Newswire associated0

FDA Meeting Feedback Puts Turn Biotechnologies on Track to be First Longevity Company Taking Cell Rejuvenation Therapy to Clinic

PR Newswire associated0

Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition